Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 65%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, b...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 53 5611 3511
Address:
58 Middle Beijing Road, Yantai Development Zone Yantai Area of Shandong Pilot Free Trade, Yantai, China
Latest News on REGMF
No data available.